SPLENIC MARGINAL ZONE LYMPHOMA
Clinical trials for SPLENIC MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SPLENIC MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for SPLENIC MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Scientists test Triple-Threat attack on Tough-to-Treat lymphomas
Disease control OngoingThis early-stage trial is testing a new combination of three drugs for people whose non-Hodgkin lymphoma has come back after previous treatment. The main goal is to find the safest and most effective dose of a new pill (PCI-32765) when given with two existing drugs (rituximab and…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Apr 04, 2026 05:05 UTC
-
New drug combo tested to fight rare lymphoma
Disease control OngoingThis study is testing if a two-drug combination (rituximab plus zanubrutinib) works better and is as safe as a single drug (rituximab alone) for people with a specific type of blood cancer called splenic marginal zone lymphoma who haven't had treatment before. About 122 participa…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE3 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Scientists test re-engineered 'Living Drug' to hunt lymphoma
Disease control OngoingThis early-phase study is testing the safety and best dose of a personalized cell therapy for patients with aggressive B-cell lymphomas that have returned or are high-risk. The treatment involves collecting a patient's own immune cells (T cells), genetically modifying them in a l…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New drug duo aims to control rare blood cancer
Disease control OngoingThis study is testing the safety and effectiveness of combining two existing drugs, ibrutinib and rituximab, for people newly diagnosed with a slow-growing blood cancer called marginal zone lymphoma. The trial will enroll 175 adults who have not yet received any chemotherapy or i…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New strategy aims to tame dangerous virus after cancer transplant
Disease control OngoingThis study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC